North America Nuclear Imaging Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

North America Nuclear Imaging Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The North America nuclear imaging market is expected to grow with a CAGR of 7% during the forecasted period. Certain factors that are propelling the growth of the market include technological advancements, increasing diagnostic applications in various diseases, such as cancer and cardiovascular diseases, government support, and a shift from standalone to hybrid modalities. Nuclear imaging has a crucial role in the treatment of several diseases associated with Cardiology, Neurology, orthopedics, etc. Diagnosis through nuclear imaging helps in detecting several diseases such as Cancer. According to the estimates of the American Cancer Society, in 2018, there are around 1,735,350 new cancer cases diagnosed and 609,640 deaths, due to cancer in the United States. The rising prevalence of cancer in the United States will surge the demand for better diagnosis options and further, it will directly trigger the overall market growth.

Moreover, technological advancements in the field of imaging have always been challenging to practitioners in how best to optimize them inpatient care. Over recent years, scientists, researchers, and technologists have been able to bring systems in clinical practice, in which two or even more than two standalone diagnostic imaging modalities are combined. Some of those multimodality imaging systems include PET/CT, SPECT/CT, PET/MRI, and PET/SPECT/CT.

Moreover, the rise in the prevalence of cancer and cardiac ailments is one of the primary drivers for the market. Nuclear medicine is hugely capable of treating cancer and cardiac diseases. There is significant evidence, which proves that diagnosing with nuclear imaging techniques has more impact on patient management for monitoring tumor and also its response to the drug.

Key Market TrendsOncology is Expected to hold the Highest Market Share in PET Applications

The prevalence of various types of cancer has shown a significant rise over the past two decades. According to the statistics of the Lymphoma Research Foundation, each year, more than 100,000 people are diagnosed with lymphoma, and nearly one million people in the United States are living with, or are in remission from, lymphoma. It is the third-most-common cancer in children.

The FDG-PET/CT is more sensitive than a contrast-enhanced CT scan in the staging of several types of lymphoma or in detecting tumor dissemination in several solid cancers, such as breast cancer, lung cancer, and colon cancer.

In the field of oncology, the PET (positron emission tomography) uses FDG (18Fluorine-2-fluoro-2-Deoxy-d-glucose) as the radiopharmaceutical, as it demonstrates the increased metabolism by malignant cells when compared to that of normal cells. Furthermore, there is continuous technological progress in the field of image generation. The introduction of sophisticated software to use PET scan as a biomarker has facilitated new ways to calculate new prognostic markers, such as the metabolic tumor volume (MTV) and the total amount of tumor glycolysis (TLG). The 18F-fluorodeoxyglucose (18F-FDG) has high sensitivity, but it is not tumor specific. This technique can be used for the imaging of lung cancer, lymphoma, head and neck tumors, breast cancer, esophageal cancer, colorectal cancer, and urinary tract tumors. Hence, all the aforementioned technological advancements are expected to drive growth in this segment of the market studied, over the forecast period.

Competitive Landscape

The North America Nuclear Imaging Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Bracco Imaging SpA, Cardinal Health Inc., GE Healthcare, Koninklijke Philips NV, Siemens Healthineers, Curium, CMR NAVISCAN (GAMMA MEDICA INC.), Nordion (Canada) Inc., NTP Radioisotopes SOC, Canon Medical Systems Corporation

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.